Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Proteome Sciences PLC Ord 1P (PRM)

Related News

11-Jul-2017 01:25 PM

Proteome schedules interim results release date

Proteome Sciences has confirmed that the Company will announce its interim results for the six months ended 30 June on 25 July. At 1:25pm: (LON:PRM) Proteome Sciences PLC share price was -0.05p at 3.88p Story provided by
15-Sep-2016 07:10 AM

Proteome Sciences revenues up

Proteome Sciences said revenues to 30 June increased 32% to £1.12 million (2015: £0.85 million). Licences/sales/services revenues increased 44% to £1.08m (2015: £0.75m), while TMT reagent sales increased 27%. Administrative expen
01-Dec-2014 03:28 PM

Proteome Sciences appoints company secretary

Proteome Sciences has confirmed that James Malthouse has, as announced on 30 September, retired today as a director and as company secretary. Finance director Geoffrey Ellis has been appointed as company secretary. At 3:28pm: (LON:PRM) Proteome Science
12-Nov-2014 09:21 AM

Proteome contract delays

Proteome Sciences said anticipated contract delays means revenue for the current year will be lower than market expectations and somewhat lower than the revenues achieved in 2013. The delayed revenues were expected to be booked in 2015, supported by str
25-Sep-2014 10:24 AM

Preotome Sciences signs $2m research contract

Proteome Sciences has signed a $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy. Its PS Biomarker Services Division ("PS") has been selected to deve
07-Feb-2014 07:23 AM

Proteome Sciences sees FY revenue up significantly

Proteome Sciences said revenue for 2013 is expected be significantly higher than in 2012 due to the strong performances across its core activities. "The Orbitrap Fusion mass spectrometer provided as part of the licensing deal with Thermo Fisher Sci
04-Dec-2013 07:30 AM

Proteome says some contract revenue delayed beyond Q4

Proteome Sciences sales lead times however have taken longer than anticipated and the timing and revenue from a number of other contracts expected in the fourth quarter has been delayed and is now projected to fall into 2014. "Our pipeline and the
30-Sep-2013 08:56 AM

Proteome Sciences H1 pretax loss widens to £1.9m

Proteome Sciences' H1 pretax loss widened to £1.9m, from a loss of £1.7m. Total revenue was £0.89m, from £0.81m. "Our core activities are performing well and we hope to show a considerable increase in revenue for the full year with that perf
18-Sep-2013 02:17 PM

Proteome Sciences presents data at HUPO

Proteome Sciences presented novel data and key assay developments at the HUPO 12th Annual World Congress in Japan. The data covered Tau in Alzheimer's disease, SysQuant in pancreatic cancer and a missing isoform in sugar structures of clusterin, a p
06-Aug-2013 12:41 PM

Shares issue at Proteome Sciences raises £1.57m

Proteome Sciences has received a direct approach from an institutional investor to subscribe for 3,750,000 new ordinary shares at a price of 41.5p per share. The issue raised approximately £1.57m which will be used as additional working capital to dev
28-Jun-2013 01:08 PM

Proteome Sciences expects sharp increase in revenues

Proteome Sciences expects a sharp increase in group revenue in 2013, the company's annual general meeting statement says. The group says its commercial activities are benefiting from its technology development and the rapid increase in the numbers
12-Jun-2013 07:19 AM

Proteome Sciences confirms $2.1m technology contract

Proteome Sciences has confirmed its largest contract to date, a technology agreement with Thermo Fisher Scientific, valued at $2.1million by Proteome Sciences, to develop advanced methods to profile changes in key cancer pathways. Proteome Sciences woul
30-May-2013 07:50 AM

Preteome Sciences widens FY pretax loss to £5.2m

Preteome Sciences widened its full-year pretax loss to £5.2 million, from £4.5 million. Revenue was £1.2 million, from £1.0 million. "Protein biomarkers are receiving increasing prominence and attention and we are benefiting from a broad and gro
22-Jan-2013 08:28 AM

Proteome Sciences says contract delay to dent FY 2012 results

Proteome Sciences said in a trading statement that it expects strong revenue growth across its three main divisions in 2013, but that its full-year results will be dented by a contract delay. and looks to the future with confidence. The company said it
20-Aug-2012 08:16 AM

Proteome Sciences to collaborate with CHDI Foundation

Proteome Sciences has announced it will collaborate with CHDI Foundation, Inc. on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services�?¢ protein profiling to CHDI's research
05-Apr-2012 08:16 AM

Proteome grants biomarker licence to Randox

Proteome Sciences has today granted a non-exclusive licence to Randox Laboratories for its portfolio of stroke biomarkers. Under the terms of the agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment
22-Dec-2011 09:33 AM

Proteome confirms progress on Alzheimer's target

Proteome Sciences has confirmed that selected compounds, previously identified as potential inhibitors against CK1δ, have now been tested in cells and have shown strong activity. Further IP has been filed to cover the results which the Directors believ
26-Jul-2011 08:46 AM

Proteome Sciences appoint Barney for US business role

Proteome Sciences has appointed Glenn Barney as VP Business Development in North America. Prior to joining the Proteome Sciences team, Barney was the VP Business Development for NextGen Sciences Inc. and was responsible for the commercialization of a s
07-Jul-2011 08:37 AM

Proteome to work with Moffitt on cancer research

Proteome Sciences plc a global leader in applied proteomics has entered into a collaboration agreement with Moffitt Cancer Center. Under the agreement, Proteome will support research to develop mass spectrometry assays measuring certain key signalling an
27-May-2011 09:17 AM

Proteome Sciences confident about prospects

Proteome Sciences has reported a strong swing back to profits after the receipt of Euro 11m following the settlement of a warranty claim against Sanofi-Aventis. Pre-tax profits for the year to 31 December 2010, including the Euro 11m receipt, were £4.
20-Dec-2010 11:22 AM

Proteome Sciences closes biomarker contract with Janssen

Proteome Sciences plc has signed a research contract with Belgium's Janssen Pharmaceutica NV, part of the Johnson & Johnson group. PS Biomarker Services will use a combination of its proprietary TMT isobaric mass tag technology, sample preparation
30-Nov-2010 12:11 PM

Proteome warns of loss after contract delays

Research group Proteome Sciences plc said it was unlikely to make a pre-tax profit in 2010 because of contract delays but expected to report a profit before exceptionals following a successful warranty claim against Sanofi-Aventis. The group had previous
28-Sep-2010 12:06 PM

Proteome gets €11m Sanofi settlement

Biotech R&D company Proteome Sciences will receive €11m tomorrow (September 29) following settlement of a dispute with Sanofi-Aventis dating back to 2002. Proteome Sciences filed a court claim for breach of contractual and statutory obligations by
23-Sep-2010 12:30 PM

Proteome sees new revenue opportunities from Thermo Fisher deal

Proteome Sciences announced an additional collaboration with Thermo Fisher Scientific Inc. to deliver innovative products in protein biomarker research and further develop quantitative proteomic workflows for biomarker discovery and validation. The compa
18-Jun-2010 09:46 AM

Proteome gets word on German claim hearing

Research and development company Proteome Sciences has been notified by the Higher Regional Court in Frankfurt that it intends to take witness evidence at the end of July in connection with the company's warranty claim against Sanofi. Proteome says
Top categories
Company finder

a d v e r t i s e m e n t